Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Unspecified Respiratory Disorders.

N-115 is under clinical development by EmphyCorp and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

15ml Large Capacity and Whisper-Quiet Operation: Equipped with an advanced silent chip, our nebulizer operates at less than 28 dB, ensuring a peaceful treatment experience without noise distractions.

Two Phase 3 clinical results of Dupixent were released to relieve sinusitis and asthma Nature Focus: Research finds that human biological age can be reversed to an average of 2.5 years younger IDEAYA ...

“Dr. Chen Chih-jung of Linkou Chang Gung Memorial Hospital stated in an interview on Thursday that hMPV is similar to ...

A POPULAR nasal spray used to tackle a blocked nose may trigger Parkinson’s disease-like ... The NHS says that while some people experience no side effects, many side effects subside after the first ...